INCY News and Press, Incyte Corporation From 02/28/21

This investment strategy holds a maximum of 50 consensus stock picks from 40 hedge funds with more than $3,500 million Assets Under Management. Changes in the holdings occur only every three months when the end of the quarter 13F filings become public information; the latest date was ...

The EMA has validated Incyte's (INCY) Marketing Authorization Application ((MAA)) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma ((SCAC)) who are intolerant of, platinum-based chemot...

Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who ...

Today, we take our first in depth look at CTI BioPharma, that looks like it might finally garner its first FDA approval. The company is aiming its primary drug candidate as a lucrative niche of the myelofibrosis market. An analysis on CTI BioPharma is presented in the paragraphs b...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi ® ) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult ...

The FDA has accepted with Priority Review Incyte's (INCY) NDA for ruxolitinib cream for atopic dermatitis.Ruxolitinib is a selective JAK1/JAK2 inhibitor.NDA backed by data from the phase 3 TRuE-AD clinical trial that included more than 1,200 people.The PDUFA date is June 21, 2021.Incyte share...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, as a treatment for atopic dermatitis (AD), a typ...

Even eliminating a $110 milestone payment, revenue was up 17% y/y. Several new products are in launch phase, so expect more revenue growth. The pipeline is extensive, so new products could launch throughout the decade. For further details see: Incyte Q4 2020 Shows Streng...

Incyte was a buy, with share price at $85.61 in December 2020. The share price subsequently increased to $101.47. The share price has currently dipped to $85.17, providing another buy opportunity. For further details see: Incyte: Another Buy Opportunity

There is no cure for alopecia areata and the latter affects as many as 6.8 million people in the U.S. alone. Concert is among the several companies developing a drug and it aims to present an NDA submission in early 2023. However, I doubt it will be the first to reach the market a...